Zurich, 26 November 2020 – Achiko AG (SWX:ACHI, ISIN CH0522213468) announces the completion of a convertible loan facility with US based fund manager Yorkville Advisors Global LP (“Yorkville”), signing a convertible loan facility of up to USD 12 million. It is constituted of a committed USD 2.5 … [Read more...]
Achiko AG appoints Toolbox Medical Innovations and NDA Group and expands Advisory Board
Encouraging initial results to date in field validation trialsToolbox Medical Innovations engaged for the design of the commercial test kitNDA Group engaged to assist in progress towards CE markingAdditional international advisory board members: Paul Field (Australia) and Charles Pan … [Read more...]
Achiko AG Completes Capital Increase
Zurich, 30 October 2020 – Achiko AG (SWX:ACHI, ISIN CH0522213468) announces that following the financing round communicated on the 29th July 2020, its share capital recorded in the commercial register has been increased by 13,165,476 shares to 102,797,618 shares. The new shares have been issued out … [Read more...]
Achiko Establishes Medtech Expert Advisory Board and Expands Management Team
New international advisory board members: Mr Glenn Cross (Australia), Dr Jittaporn Wattanaseree (Thailand) and Ms Carol Aebi (Switzerland)Management team appointment: Mr Pierre Nathie of Med2Mark as VP, CommercialisationZurich, 13 October 2020--Achiko AG (SWX:ACHI, ISIN CH0522213468) is pleased … [Read more...]
Achiko AG Announces Half-Year Results per June 30 2020
The outbreak of the Covid-19 pandemic towards the end of first quarter 2020 limited Achiko’s ability to execute on its business strategyAchiko responded by developing a Covid-19 testing and ecosystem platform Teman Sehat, and by securing a complementary testing technology codenamed “Gumnuts” to … [Read more...]